[Articles] Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

Di |2024-05-24T00:30:01+02:00Maggio 24th, 2024|Categorie: Coronavirus Lancet|

Doxycycline PEP strongly reduced the incidence of chlamydia and syphilis in MSM, but we did not show efficacy of the 4CmenB vaccine for gonorrhoea. Doxycycline PEP should be assessed in other populations, such as heterosexual men and women, and its eff...

[Corrections] Correction to Lancet Infect Dis 2024; published online April 30. https://doi.org/10.1016/S1473-3099(24)00215-9

Di |2024-05-24T00:30:01+02:00Maggio 24th, 2024|Categorie: Coronavirus Lancet|

Ares-Gómez S, Mallah N, Santiago-Pérez M-I, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudina...

[Articles] Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Di |2024-05-18T00:30:01+02:00Maggio 18th, 2024|Categorie: Coronavirus Lancet|

For DS-TB, BPaMZ successfully met the primary efficacy endpoint of sputum culture conversion. The regimen did not meet the key secondary efficacy endpoint due to adverse events resulting in treatment withdrawal. Our study demonstrated the potential for...

[Comment] A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis

Di |2024-05-18T00:30:01+02:00Maggio 18th, 2024|Categorie: Coronavirus Lancet|

In 1948, the pioneering study that introduced streptomycin as the first treatment for tuberculosis (TB) was published, but the rapid onset of drug-resistant strains restricted the long-term benefit of streptomycin monotherapy.1 This led to the explorat...

[Articles] Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study

Di |2024-05-16T00:30:01+02:00Maggio 16th, 2024|Categorie: Coronavirus Lancet|

Compared with other SARS-CoV-2 variants, BA.2.86 and the JN.1 sublineage were less sensitive to vaccine-induced immune protection from the XBB.1.5 updated COVID-19 vaccine; however, we found no evidence that infection with BA.2.86 or JN.1 resulted in i...

Torna in cima